434 related articles for article (PubMed ID: 26057757)
21. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
[TBL] [Abstract][Full Text] [Related]
22. CONVERSION TO AFLIBERCEPT THERAPY VERSUS CONTINUING WITH RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEPENDENT ON MONTHLY RANIBIZUMAB TREATMENT.
Mantel I; Gianniou C; Dirani A
Retina; 2016 Jan; 36(1):53-8. PubMed ID: 26166797
[TBL] [Abstract][Full Text] [Related]
23. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
[TBL] [Abstract][Full Text] [Related]
24. Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.
Monés J; Biarnés M;
Eur J Ophthalmol; 2020 Sep; 30(5):1082-1090. PubMed ID: 31088111
[TBL] [Abstract][Full Text] [Related]
25. Quantitative OCT subanalysis of eyes with choroidal neovascularization switched from multiple injections of bevacizumab or ranibizumab to intravitreal aflibercept.
Hariri A; Diniz B; Fou LV; Lam LA; Nittala MG; Sadda SR
Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):195-200. PubMed ID: 25707044
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration.
Muftuoglu IK; Arcinue CA; Tsai FF; Alam M; Gaber R; Camacho N; You Q; Freeman WR
Am J Ophthalmol; 2016 Jul; 167():1-9. PubMed ID: 27049000
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration.
Heussen FM; Shao Q; Ouyang Y; Joussen AM; Müller B
Graefes Arch Clin Exp Ophthalmol; 2014 Jun; 252(6):909-15. PubMed ID: 24362854
[TBL] [Abstract][Full Text] [Related]
28. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.
Waldstein SM; Simader C; Staurenghi G; Chong NV; Mitchell P; Jaffe GJ; Lu C; Katz TA; Schmidt-Erfurth U
Ophthalmology; 2016 Jul; 123(7):1521-9. PubMed ID: 27157149
[TBL] [Abstract][Full Text] [Related]
29. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P
BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
[TBL] [Abstract][Full Text] [Related]
31. Durability of every-8-week aflibercept maintenance therapy in treatment-experienced neovascular age-related macular degeneration.
Dans KC; Freeman SR; Lin T; Meshi A; Olivas S; Cheng L; Amador-Patarroyo MJ; Freeman WR
Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):741-748. PubMed ID: 30806775
[TBL] [Abstract][Full Text] [Related]
32. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).
Wykoff CC; Brown DM; Maldonado ME; Croft DE
Br J Ophthalmol; 2014 Jul; 98(7):951-5. PubMed ID: 24518078
[TBL] [Abstract][Full Text] [Related]
33. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.
Wang X; Sawada T; Sawada O; Saishin Y; Liu P; Ohji M
Am J Ophthalmol; 2014 Oct; 158(4):738-744.e1. PubMed ID: 24973606
[TBL] [Abstract][Full Text] [Related]
34. Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration.
Kent JS; Iordanous Y; Mao A; Powell AM; Kent SS; Sheidow TG
Can J Ophthalmol; 2012 Apr; 47(2):159-64. PubMed ID: 22560422
[TBL] [Abstract][Full Text] [Related]
35. Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability.
Nomura Y; Yanagi Y
Jpn J Ophthalmol; 2015 Jul; 59(4):261-5. PubMed ID: 25983109
[TBL] [Abstract][Full Text] [Related]
36. AFLIBERCEPT FOR THE TREATMENT OF RETINAL PIGMENT EPITHELIAL DETACHMENTS.
He L; Silva RA; Moshfeghi DM; Blumenkranz MS; Leng T
Retina; 2016 Mar; 36(3):492-8. PubMed ID: 26398694
[TBL] [Abstract][Full Text] [Related]
37. Aflibercept in the treatment of neovascular age-related macular degeneration in previously treated patients.
Hall LB; Zebardast N; Huang JJ; Adelman RA
J Ocul Pharmacol Ther; 2014 May; 30(4):346-52. PubMed ID: 24552305
[TBL] [Abstract][Full Text] [Related]
38. Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration.
Zinkernagel MS; Wolf S; Ebneter A
Ophthalmologica; 2016; 235(1):42-8. PubMed ID: 26540259
[TBL] [Abstract][Full Text] [Related]
39. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
[TBL] [Abstract][Full Text] [Related]
40. INFLUENCE OF VITREOMACULAR INTERFACE ON ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY USING TREAT AND EXTEND TREATMENT PROTOCOL FOR AGE-RELATED MACULAR DEGENERATION (VINTREX).
Houston SK; Rayess N; Cohen MN; Ho AC; Regillo CD
Retina; 2015 Sep; 35(9):1757-64. PubMed ID: 26110596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]